Bertino JR - Search Results

1

Anti-Tumor Effects of a Penetratin Peptide Targeting Transcription of E2F-1, 2 and 3a Is Enhanced When Used in Combination with Pemetrexed or Cisplatin.

Rather GM, Anyanwu M, Minko T, Garbuzenko O, Szekely Z, Bertino JR. Rather GM, et al. Among authors: bertino jr. Cancers (Basel). 2021 Feb 26;13(5):972. doi: 10.3390/cancers13050972. Cancers (Basel). 2021. PMID: 33652640 Free PMC article.

2

Modeling and antitumor studies of a modified L-penetratin peptide targeting E2F in lung cancer and prostate cancer.

Shaik T, Rather GM, Bansal N, Minko T, Garbuzenko O, Szekely Z, Abali EE, Banerjee D, Kerrigan JE, Scotto KW, Bertino JR. Shaik T, et al. Among authors: bertino jr. Oncotarget. 2018 Sep 7;9(70):33249-33257. doi: 10.18632/oncotarget.26064. eCollection 2018 Sep 7. Oncotarget. 2018. PMID: 30279956 Free PMC article.

3

Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer.

Xie X, Kerrigan JE, Minko T, Garbuzenko O, Lee KC, Scarborough A, Abali EE, Budak-Alpdogan T, Johnson-Farley N, Banerjee D, Scotto KW, Bertino JR. Xie X, et al. Among authors: bertino jr. Cancer Biol Ther. 2013 Aug;14(8):742-51. doi: 10.4161/cbt.25184. Epub 2013 Jun 3. Cancer Biol Ther. 2013. PMID: 23792570 Free PMC article.

4

A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts.

Xie X, Bansal N, Shaik T, Kerrigan JE, Minko T, Garbuzenko O, Abali EE, Johnson-Farley N, Banerjee D, Scotto KW, Bertino JR. Xie X, et al. Among authors: bertino jr. Oncotarget. 2014 Feb 28;5(4):901-7. doi: 10.18632/oncotarget.1809. Oncotarget. 2014. PMID: 24658650 Free PMC article.

5

Activated matriptase as a target to treat breast cancer with a drug conjugate.

Rather GM, Lin SY, Lin H, Banach-Petrosky W, Hirshfield KM, Lin CY, Johnson MD, Szekely Z, Bertino JR. Rather GM, et al. Among authors: bertino jr. Oncotarget. 2018 May 25;9(40):25983-25992. doi: 10.18632/oncotarget.25414. eCollection 2018 May 25. Oncotarget. 2018. PMID: 29899836 Free PMC article.

6

A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma.

Rather GM, Lin SY, Lin H, Szekely Z, Bertino JR. Rather GM, et al. Among authors: bertino jr. Front Oncol. 2019 Apr 10;9:258. doi: 10.3389/fonc.2019.00258. eCollection 2019. Front Oncol. 2019. PMID: 31024856 Free PMC article.

7

In cancer, all roads lead to NADPH.

Rather GM, Pramono AA, Szekely Z, Bertino JR, Tedeschi PM. Rather GM, et al. Among authors: bertino jr. Pharmacol Ther. 2021 Oct;226:107864. doi: 10.1016/j.pharmthera.2021.107864. Epub 2021 Apr 22. Pharmacol Ther. 2021. PMID: 33894275 Review.

8

Toward point-of-care assessment of patient response: a portable tool for rapidly assessing cancer drug efficacy using multifrequency impedance cytometry and supervised machine learning.

Ahuja K, Rather GM, Lin Z, Sui J, Xie P, Le T, Bertino JR, Javanmard M. Ahuja K, et al. Among authors: bertino jr. Microsyst Nanoeng. 2019 Jul 15;5:34. doi: 10.1038/s41378-019-0073-2. eCollection 2019. Microsyst Nanoeng. 2019. PMID: 31645995 Free PMC article.

9

Rapid Assessment of Surface Markers on Cancer Cells Using Immuno-Magnetic Separation and Multi-frequency Impedance Cytometry for Targeted Therapy.

Lin Z, Lin SY, Xie P, Lin CY, Rather GM, Bertino JR, Javanmard M. Lin Z, et al. Among authors: bertino jr. Sci Rep. 2020 Feb 20;10(1):3015. doi: 10.1038/s41598-020-57540-7. Sci Rep. 2020. PMID: 32080205 Free PMC article.

10

NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview.

Pramono AA, Rather GM, Herman H, Lestari K, Bertino JR. Pramono AA, et al. Among authors: bertino jr. Biomolecules. 2020 Feb 26;10(3):358. doi: 10.3390/biom10030358. Biomolecules. 2020. PMID: 32111066 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

711 results

Search Page